Stocks News

LAST PRICE
229.5800
TODAY'S CHANGE (%)
0.0000 (0.0000%)

Bid / Lots
218.0000/ 1
Ask / Lots
264.0000/ 1
Open / Previous Close
234.8100 / 229.5800
Day Range
Low 228.6300
High 235.2800
52 Week Range
Low 119.7604
High 300.9999
Volume
374,487
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

May 17, 2024
- Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing, from 3:08AM ET on Friday May 17, 2024 by MT Newswires
  3:08AM ET on Friday May 17, 2024 by MT Newswires
  Companies Mentioned: MDGL
  03:08 AM EDT, 05/17/2024 (MT Newswires) -- Fred B Craves, Director, on May 14, 2024, sold 22,489 shares in Madrigal Pharmaceuticals (MDGL) for $4,787,404. Following the Form 4 filing with the SEC, Craves has control over a total of 489,685 shares of...
May 10, 2024
- DJ Madrigal Pharmaceuticals Is Maintained at Neutral by B. Riley Securities, from 8:55AM ET on Friday May 10, 2024 by Dow Jones
  8:55AM ET on Friday May 10, 2024 by Dow Jones
  Companies Mentioned: MDGL
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 10, 2024 08:55 ET (12:55 GMT)
- B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating, from 8:51AM ET on Friday May 10, 2024 by MT Newswires
  8:51AM ET on Friday May 10, 2024 by MT Newswires
  Companies Mentioned: MDGL
  08:51 AM EDT, 05/10/2024 (MT Newswires) -- Madrigal Pharmaceuticals (MDGL) has an average rating of outperform and price targets ranging from $155 to $372, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and econom...
May 9, 2024
- UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating, from 10:53AM ET on Thursday May 09, 2024 by MT Newswires
  10:53AM ET on Thursday May 09, 2024 by MT Newswires
  Companies Mentioned: MDGL
  10:53 AM EDT, 05/09/2024 (MT Newswires) -- Madrigal Pharmaceuticals (MDGL) has an average outperform rating and price target range of $150 to $507, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic resea...
May 8, 2024
- DJ Madrigal Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co., from 3:42PM ET on Wednesday May 08, 2024 by Dow Jones
  3:42PM ET on Wednesday May 08, 2024 by Dow Jones
  Companies Mentioned: MDGL
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 08, 2024 15:42 ET (19:42 GMT)

May 24, 2024
- BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting, from 7:30AM ET on Friday May 24, 2024 by GlobeNewswire
  7:30AM ET on Friday May 24, 2024 by GlobeNewswire
  Companies Mentioned: BBIO
May 23, 2024
- Raymond James Adjusts Price Target on Cytokinetics to $70 From $92, Maintains Outperform Rating, from 10:45AM ET on Thursday May 23, 2024 by MT Newswires
  10:45AM ET on Thursday May 23, 2024 by MT Newswires
  Companies Mentioned: CYTK
- Sector Update: Health Care Stocks Flat to Lower Premarket Thursday, from 9:12AM ET on Thursday May 23, 2024 by MT Newswires
  9:12AM ET on Thursday May 23, 2024 by MT Newswires
  Companies Mentioned: IBB, MDT, XLV, TNGX, CYTK
- Needham Adjusts Price Target on Cytokinetics to $72 From $108, Maintains Buy Rating, from 9:01AM ET on Thursday May 23, 2024 by MT Newswires
  9:01AM ET on Thursday May 23, 2024 by MT Newswires
  Companies Mentioned: CYTK
- Nvidia Earnings Fuel Investor Optimism, Driving Premarket Gains for US Equity Futures, from 8:50AM ET on Thursday May 23, 2024 by MT Newswires
  8:50AM ET on Thursday May 23, 2024 by MT Newswires
  Companies Mentioned: NVDA, DELL, VFS, CYTK
- Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Tech Stocks Rally on NVIDIA Earnings, from 8:32AM ET on Thursday May 23, 2024 by MT Newswires
  8:32AM ET on Thursday May 23, 2024 by MT Newswires
  Companies Mentioned: GLD, FAS, FAZ, IBB, IGM, IGV, SOXX, IVV, IWM, IYE, IYH, IYJ, IYK, IYW, NVDA, QQQ, SPY, TD, VDC, VFC, VHT, VIS, XLE, XLF, XLI, XLK, XLP, XLV, XLY, XSD, RTH, USO, BORR, SLV, VRT, XRT, EXI, BITO, UNG, CYTK, EEM
- Top Premarket Decliners, from 7:59AM ET on Thursday May 23, 2024 by MT Newswires
  7:59AM ET on Thursday May 23, 2024 by MT Newswires
  Companies Mentioned: VFC, RDZN, CYTK, TITN
- Cytokinetics Prices $500 Million Common Stock Offering, from 4:52AM ET on Thursday May 23, 2024 by MT Newswires
  4:52AM ET on Thursday May 23, 2024 by MT Newswires
  Companies Mentioned: CYTK
May 22, 2024
- Cytokinetics Announces Pricing of Public Offering of Common Stock, from 11:31PM ET on Wednesday May 22, 2024 by GlobeNewswire
  11:31PM ET on Wednesday May 22, 2024 by GlobeNewswire
  Companies Mentioned: CYTK
- Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline, from 5:00PM ET on Wednesday May 22, 2024 by MT Newswires
  5:00PM ET on Wednesday May 22, 2024 by MT Newswires
  Companies Mentioned: RPRX, CYTK

Madrigal Pharmaceuticals Inc
NASDAQ:MDGLUnited States

Search Criteria

May 17, 2024

Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing, from 3:08AM ET on Friday May 17, 2024 by MT Newswires

May 10, 2024

DJ Madrigal Pharmaceuticals Is Maintained at Neutral by B. Riley Securities, from 8:55AM ET on Friday May 10, 2024 by Dow Jones

B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating, from 8:51AM ET on Friday May 10, 2024 by MT Newswires

May 9, 2024

UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating, from 10:53AM ET on Thursday May 09, 2024 by MT Newswires

May 8, 2024

DJ Madrigal Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co., from 3:42PM ET on Wednesday May 08, 2024 by Dow Jones

Peers Headlines

May 24, 2024

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting, from 7:30AM ET on Friday May 24, 2024 by GlobeNewswire

May 23, 2024

Raymond James Adjusts Price Target on Cytokinetics to $70 From $92, Maintains Outperform Rating, from 10:45AM ET on Thursday May 23, 2024 by MT Newswires

Sector Update: Health Care Stocks Flat to Lower Premarket Thursday, from 9:12AM ET on Thursday May 23, 2024 by MT Newswires

Needham Adjusts Price Target on Cytokinetics to $72 From $108, Maintains Buy Rating, from 9:01AM ET on Thursday May 23, 2024 by MT Newswires

Nvidia Earnings Fuel Investor Optimism, Driving Premarket Gains for US Equity Futures, from 8:50AM ET on Thursday May 23, 2024 by MT Newswires

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Tech Stocks Rally on NVIDIA Earnings, from 8:32AM ET on Thursday May 23, 2024 by MT Newswires

Top Premarket Decliners, from 7:59AM ET on Thursday May 23, 2024 by MT Newswires

Cytokinetics Prices $500 Million Common Stock Offering, from 4:52AM ET on Thursday May 23, 2024 by MT Newswires

May 22, 2024

Cytokinetics Announces Pricing of Public Offering of Common Stock, from 11:31PM ET on Wednesday May 22, 2024 by GlobeNewswire

Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline, from 5:00PM ET on Wednesday May 22, 2024 by MT Newswires